Asciminib Treatment Optimization in ā„ 3rd Line CML-CP
Novartis
Novartis
National Institutes of Health Clinical Center (CC)
Takeda
University of Illinois at Chicago
Centre Oscar Lambret
Institut Paoli-Calmettes
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
University of Chicago
Incyte Corporation
University of Nebraska
Henan University
Massachusetts General Hospital
Institute of Hematology & Blood Diseases Hospital, China
M.D. Anderson Cancer Center
Massachusetts General Hospital
Roswell Park Cancer Institute
Group for Research in Adult Acute Lymphoblastic Leukemia
Gamida Cell ltd
Columbia University
National Institutes of Health Clinical Center (CC)
BeOne Medicines
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Merck Sharp & Dohme LLC
University of Kentucky
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Bristol-Myers Squibb
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, China
Mayo Clinic
University of Rochester
iOMEDICO AG
Abramson Cancer Center at Penn Medicine
University of Rochester
National Research Center for Hematology, Russia
Eli Lilly and Company
H. Lee Moffitt Cancer Center and Research Institute
First Affiliated Hospital of Zhejiang University
Danone Asia Pacific Holdings Pte, Ltd.
Children's Hospital Los Angeles
Novartis
Baylor College of Medicine
National Institutes of Health Clinical Center (CC)
University of Iowa
Fondazione IRCCS Policlinico San Matteo di Pavia
Thomas Jefferson University
BeOne Medicines